Seclidemstat
- Generic Name
- Seclidemstat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23ClN4O4S
- CAS Number
- 1423715-37-0
- Unique Ingredient Identifier
- TYH386V3WJ
- Associated Conditions
- -
- Associated Therapies
- -
FDA's July 2024 Roundup: Breakthroughs and Milestones
In July 2024, the FDA made significant strides in cancer treatment approvals and designations, including the approval of FoundationOne Liquid CDx for BRCA-mutated mCRPC and Guardant Shield for colorectal cancer detection. Fast track designations were granted to therapies like OBX-115 for melanoma and AIC100 for thyroid cancer. The FDA also accepted BLAs for treatments targeting SR-aGVHD and EBV+ PTLD, and mandated phase assessments for NSCLC perioperative regimens, aiming to improve patient outcomes.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath